Brief: Arch Biopartners Receives Approval To Perform Phase I Clincial Trial For Metablok In Australia
19/03/2019 12:49
March 19 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS RECEIVES APPROVAL TO PERFORM PHASE I
CLINCIAL
TRIAL FOR METABLOK IN AUSTRALIA
* ARCH BIOPARTNERS INC - RESULTS FROM PHASE I TRIAL ARE
EXPECTED
LATER THIS YEAR
* ARCH BIOPARTNERS INC - GRANTED APPROVAL BY ALFRED HOSPITAL
ETHICS COMMITTEE TO PERFORM A PHASE I CLINICAL TRIAL FOR
METABLOK
Source text for Eikon: ID:nGNX195164
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide